Tapimmune - TPIV

Tapimmune (TPIV)
http://www.tapimmune.com
Coverage: January 21, 2010 - March 21, 2010
Featured: January 21, 2010

Latest Newsletter Editions

spacer
Sat, May 22, 2010 @ 02:05 pm
There was a little relief rally on Friday after a fairly wicked week in the markets. Thursday's giant sell down felt like a "cash at any cost" down draft, with almost no regard for value. That's fine with me. These kinds of emotional, momentum driven markets present opportunities for those with the...
Tue, May 18, 2010 @ 10:05 am
A Busy Day- Comments on a Bunch of Stuff Frankly, it's a bit annoying. I wish these smaller companies could get their quarterly numbers out over a few week period in time, instead of all in one or two days at the absolute deadline. I just can't get quality commentary out fast enough for investors to...
Mon, Feb 1, 2010 @ 03:02 pm
Nothing Like a Cool $200 Million You might wonder who's got the cool $200 million, and what it has to do with today's edition of the OTC Journal. Remember my short term trading idea?- TapImmune (OTC BB: TPIV) I said some positive developments would start to roll their way, and today's post close news...
Wed, Jan 27, 2010 @ 09:01 am
Two Beat Downs; Stand By I just wanted to publish a couple of quick notes on two stocks I've been covering and have made comments on recently. First on China Recycling Energy (CREG)- someone is selling the stock fairly ruthlessly with little regard for price. It started two days ago, and the stock is...
Thu, Jan 21, 2010 @ 01:01 pm
How The Immune System Fights Disease Our bodies have a miraculous capability. Our Immune System, through a complex network of cells and chemicals, has the ability to identify bad stuff and rapidly recruit an army to attack foreign invaders and kill them. T-Cells are the circus ring masters. The T-Cells...

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: Bid x Ask Size:
Change: +0.0000 (+0.00%) Day's Range: 0.00 - 0.00
Prev Close: 0.0000 52wk Range: 0.00 - 0.00
Open: 0.0000 P/E (ttm):
Volume: 0 EPS (ttm):
spacer [Chart]

Business Summary

spacer
TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.

Disclosure

spacer
MarketByte LLC has purchased 400,000 shares of Tapimmune with a cost basis of 7.5 cents from a non affiliate shareholder. The shares are freely tradeable. This should be construed as a form of compensation and a conflict of interest. The aforementioned shares could be sold at anytime without prior notification.

Recent News Headlines

spacer
TapImmune Appoints John Bonfiglio as Strategic Advisor
Wed, 25 Feb 2015 20:10:50 GMT
[at noodls] - 25 Feb Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise SEATTLE, Feb. 25, 2015 - TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John Bonfiglio, ...
TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer
Wed, 25 Feb 2015 20:10:50 GMT
[at noodls] - 23 Feb SEATTLE, Feb. 23, 2015 - TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to ...
TapImmune Appoints John Bonfiglio as Strategic Advisor
Wed, 25 Feb 2015 13:45:00 GMT
[PR Newswire] - He was formerly President and CEO of Argos Therapeutics where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million) and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation's Immunotherapy Division. John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University.
TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer
Mon, 23 Feb 2015 13:45:00 GMT
[PR Newswire] - SEATTLE, Feb. 23, 2015 /PRNewswire/ -- TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to announce Patrick D. Yeramian, MD, MBA, has been appointed Consulting Medical Director. He will lead TapImmune's clinical development programs for folate receptor alpha and Her2/neu multi-epitope cancer technologies. These technologies have been evaluated in Phase I trials for safety and immune responses in women with breast or ovarian cancer.
TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations
Mon, 23 Feb 2015 07:32:54 GMT
[at noodls] - 19 Feb Seattle, WA & NY, NY - February 19, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious ...
TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015
Mon, 23 Feb 2015 04:41:41 GMT
[at noodls] - 20 Feb Seattle, WA - February 20, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, ...
TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015
Fri, 20 Feb 2015 14:00:00 GMT
[PR Newswire] - SEATTLE, Feb. 20, 2015 /PRNewswire/ -- TapImmune Inc . (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, ...
TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations
Thu, 19 Feb 2015 14:30:00 GMT
[PR Newswire] - After a competitive process, TapImmune determined PCG presented a team that was best matched for the Company's strategic growth plans. In addition, the PCG team presented strong knowledge of the Company's science and financial goals. Dr Glynn Wilson, Chairman & CEO of TapImmune, stated, "We determined that Jeff Ramson and his team at PCG would be the best overall fit for us. PCG's senior team has strong contacts across key U.S. Capital Markets and extensive experience in Public and Social Media. As we move TapImmune's clinical projects forward, we welcome the team's advisory services.
TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials
Tue, 10 Feb 2015 12:01:00 GMT
[Marketwired] - TapImmune Inc. , the emerging clinical-stage immunotherapy company which develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases has been grabbing ...
TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering
Tue, 13 Jan 2015 23:31:36 GMT
[at noodls] - 12 Jan Exercise in Full of Strategically Designed Warrant Package Would Result in $34,404,000 in Additional Funding Seattle, January 12, 2015 - TapImmune, Inc. (the "Company"), (otcqb:TPIV), ...
TapImmune offering would help take cancer vaccines to next clinical trials
Mon, 12 Jan 2015 21:59:33 GMT
TAPIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
Mon, 12 Jan 2015 17:06:33 GMT
Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials
Mon, 12 Jan 2015 14:15:00 GMT
[PR Newswire] - SEATTLE, Jan. 12, 2015 /PRNewswire/ -- TapImmune Inc. (TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase I clinical trial. In addition, the recent financing provides immediate, short term and long term access to the capital required to execute its exclusive option to license these very promising peptides and to progress its on-going clinical program into Phase II trials. In the Phase I Trial conducted and Mayo Clinic, results indicate safety and positive immune response data in Folate Receptor Alpha Vaccine for ovarian and breast cancers. Eight women with HER2-negative breast cancer, thirteen with ovarian cancer and one with fallopian tube cancer were enrolled. The data shows that the vaccine containing antigens to the Folate Receptor Alpha protein was very well tolerated and safe. Increased specific T-cell immune responses against a set of 5 naturally processed Folate Receptor Alpha Class II antigenic epitopes were detected in 21 of 21 evaluable patients.
TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering
Mon, 12 Jan 2015 13:48:00 GMT
[PR Newswire] - SEATTLE, Jan. 12, 2015 /PRNewswire/ -- TapImmune, Inc. (the "Company"), (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a registered ...
TAPIMMUNE INC Financials
Thu, 27 Nov 2014 18:04:25 GMT
TapImmune CEO Discusses Company’s Clinical Programs in Recent Print and Radio Interviews
Mon, 24 Nov 2014 16:00:27 GMT
[at noodls] - 24 Nov TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews In multiple industry-related media Dr Glynn Wilson discusses status of clinical programs and advancement ...
TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews
Mon, 24 Nov 2014 14:06:00 GMT
[PR Newswire] - SEATTLE, Nov. 24, 2014 /PRNewswire/ -- TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has ...
TAPIMMUNE INC Files SEC form 10-Q, Quarterly Report
Wed, 19 Nov 2014 21:57:03 GMT
TapImmune Announces Phase II Clinical Trials Collaboration with VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
Tue, 18 Nov 2014 22:20:07 GMT
[at noodls] - 18 Nov Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design SEATTLE, WASHINGTON, November 18, 2014 - TapImmune, Inc. (OTCQB: TPIV), is pleased ...
TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
Tue, 18 Nov 2014 15:00:00 GMT
[PR Newswire] - SEATTLE, Nov. 18, 2014 /PRNewswire/ --TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a ...